Atea Pharmaceuticals Files Proxy Statement
Ticker: AVIR · Form: DEFA14A · Filed: Apr 3, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | DEFA14A |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, regulatory
TL;DR
Atea Pharma filed a DEFA14A on 4/3/25, looks like standard proxy stuff, no fee paid.
AI Summary
Atea Pharmaceuticals, Inc. filed a DEFA14A on April 3, 2025, indicating it is soliciting materials under Rule 14a-12. The filing does not require a fee, as it was either not previously paid or is computed on a separate exhibit. The company is based in Boston, MA, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is a routine proxy statement, indicating the company is preparing for shareholder communication or a specific corporate action requiring shareholder input.
Risk Assessment
Risk Level: low — This is a standard DEFA14A filing, which is a routine disclosure document for public companies and does not inherently indicate significant risk.
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Registrant
- 225 Franklin Street, Suite 2100, Boston, MA 02110 (location) — Business and Mailing Address
- 460574869 (organization_id) — EIN
- 001-39661 (company_id) — SEC File Number
FAQ
What type of filing is this DEFA14A?
This is a Definitive Proxy Statement filed by Atea Pharmaceuticals, Inc.
When was this filing made?
The filing was made on April 3, 2025.
What is the company's primary business sector?
Atea Pharmaceuticals, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Atea Pharmaceuticals, Inc. located?
The company's business and mailing address is 225 Franklin Street, Suite 2100, Boston, MA 02110.
Is there a filing fee associated with this document?
No fee is required for this filing, as indicated by the checked box for 'No fee required'.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 3, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).